Jacob B. Bauer
Independent DirectorMr. Jacob B. Bauer, also known as Jake, MBA, serves as Independent Chairman of the Board of BridgeBio Oncology Therapeutics, Inc. from December 2025. Mr. Bauer is Independent Non-Executive Director of BridgeBio Oncology Therapeutics, Inc. from April 2025. He is Independent Director of Immunovant, Inc. from April 18, 2025. He is Venture Partner of SR One Capital Management, LP. He is Independent Chairman of Estuary Biotherapeutics, Inc. He served as an Independent Director at Enliven Therapeutics, Inc. since the closing of the Merger on February 23, 2023 and was appointed in connection with the closing of the Merger. Prior to the Merger, Mr. Bauer served as a member of the board of directors of Former Enliven since June 2021. He is Director of Dispatch Biotherapeutics, Inc. He serves as Chairman of the Board at Simcha Therapeutics Holding Company, LLC from August, 2022. He serves as Venture Partner at Arch Venture Partners, L.P. since joining the firm on December 1, 2021. He is focused on new company formation. He is a biotech executive and leader in the biopharmaceutical industry with a proven track record in company formation, strategy, executive and project leadership and corporate and business development. He served as Independent Director at Attralus, Inc. since July 2021. Mr. Bauer served as Assistant Secretary at MyoKardia, Inc and served as its Principal Accounting Officer. He serves as Independent Director of ARYA Sciences Acquisition Corp V since July 2021. Mr. Bauer served as an Independent Director at ARYA Sciences Acquisition Corp II from July 2020 to October 2020. He served as the Chief Business Officer of MyoKardia, Inc since April 04, 2018 and as the Senior Vice President, Finance and Corporate Development and Principal Financial Officer of MyoKardia, Inc from July 2016 to April 2018. Mr. Bauer served as Vice President of Business Development and Business Operations at MyoKardia, Inc since July 2014 until July 15, 2016. He joined MyoKardia in 2014. Mr. Bauer also currently serves on the Board of Directors of Phoenix Tissue Repair, Inc since November 2018. Mr. Bauer served as Head of Corporate Development and Vice President of Business Operations at Ablexis, LLC from May 2011 to July 2014. He served as Senior Director of Corporate Development and Business Operations at Ablexis, LLC. He was a Principal and Summer Associate at Third Rock Ventures, LLC from 2007 to 2011. He joined Third Rock Ventures in 2007 as a Senior Associate. He focused on opportunity analysis, new company formation, due diligence, deal sourcing and portfolio company support and management. In 2010, he helped open Third Rock’s office in San Francisco to support the West Coast-based portfolio companies and company creation efforts. He was actively involved in a variety of leading biopharmaceutical companies including Agios Pharmaceuticals, Inc, CytomX Therapeutics Inc., Global Blood Therapeutics, Inc and Zafgen. Mr. Bauer is involved in the formation of several portfolio companies and works with their management teams on operational and strategic issues through the first-year post launch. Prior to this, Mr. Bauer was a Management Consultant at Putnam Associates, a Member of the investment team at RP Management, LLC (formerly Royalty Pharma) and a Member of the business development group at Endo International plc (formerly Endo Pharmaceuticals). He has significant experience in the biopharmaceutical industry and also has senior leadership experience, business development and business operations experience. He served as Board Observer at Ablexis, LLC. He served as a Director of Ablexis, LLC. He currently serves on the board of Attralus, Enliven Therapeutics, Phoenix Tissue Repair, Inc. and Arya Sciences Acquisition Corp V. He serves as Director of Dispatch Therapeutics. He is a biotech executive and leader in the biopharmaceutical industry with a proven track record in company formation, strategy, executive and project leadership and corporate and business development. He holds an M.B.A. from Harvard Business School. Mr. Bauer also holds a B.S. in Biology and a B.A. in Economics from Duke University.
公司職務
- 公司名稱Immunovant, Inc.股票代碼IMVT職務Independent Director
- 公司名稱Enliven Therapeutics, Inc.股票代碼ELVN職務Independent Director共事同僚
- RARichard A. FairCEO, President & Director
- SSSamuel S. KintzCo-Founder & Head of Pipeline
- BHBenjamin HohlCFO & Head of Corporate Development
- HLHelen Louise CollinsChief Medical Officer
- JPJoseph P. LyssikatosCo-Founder & Research Fellow
- RGRishi GuptaIndependent Director
- JBJacob B. BauerIndependent Director
- SGScott GarlandDirector
- MKMika Kakefuda DerynckIndependent Director
- 公司名稱BridgeBio Oncology Therapeutics, Inc.股票代碼BBOT職務Independent Chairman of the Board共事同僚
- NKNeil KumarExecutive Chairman
- FPFrank P. McCormickCo-Founder, Non-Executive Director & Chair of the Advisory Board
- YBYong BenChief Medical & Development Officer
- PJPedro J. BeltranChief Executive Officer and Director
- MCMarc CoboVP of Finance & Controller
- JBJacob B. BauerIndependent Chairman of the Board
- PPPraveen P. TipirneniIndependent Director
